Beckman Coulter Life Sciences is taking actions in the best interests of our associates, customers, and business partners as we navigate the growing threats of the 2019 Novel Coronavirus disease (COVID-19). Learn more
What does targeting blood vessels have to do with immunotherapy?
Malignant tumors hijack the circulatory system by forming new blood vessels to sustain tumor growth in a process called angiogenesis. Newly targeted immunotherapies are geared towards interfering with pro-angiogenic signals from tumors, aiming to delay their growth and even cause them to shrink. Anti-angiogenic immunotherapy also prevents large tumors from metastasizing. Drugs which induce oxygen starvation primarily act through the vascular endothelial growth factor (VEGF) signaling pathway.1 Additional information on immunotherapy can be found in our resource center here.
1. R.R. Ramjiawan, et al., "Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?" Angiogenesis 20(2): 185-204, 2017.
Oops. The page you wanted could not be found, so we brought you to something similar. If you still can't find what you want, try searching our site instead.